Drs. Paul Marik, Robert Apter, and Mary Talley Bowden filed a federal lawsuit against the United States Food and Drug Administration regarding its public statements on ivermectin

Overview Debates Related claims Topics

The ICON study published in the journal Chest demonstrated a greater than 50% reduction in mortality among hospitalized COVID-19 patients treated with ivermectin

The Federal Trade Commission sued Nate Jones and Xlear Corporation over marketing and studies of nasal sprays and gargles against SARS-CoV-2

The Federal Trade Commission took regulatory action against Dr. Eric Nepute regarding clinical claims about vitamin D and COVID-19

In 2021, the American Medical Association issued an official policy statement calling for the cessation of ivermectin prescriptions for COVID-19

The World Health Organization and the European Society of Intensive Care Medicine issued recommendations in November 2020 advising against the use of remdesivir for COVID-19

In November 2020, Dr. Peter McCullough published the multi-drug outpatient COVID-19 treatment protocol in the American Journal of Medicine

On the day before the 2026 midterm election, the White House issued a press release highlighting drops in prescription drug prices resulting from Donald Trump's policies

Generation of reactive metabolites during medication metabolism is a compound-specific risk factor for liver toxicity

Intrinsic drug-induced liver injury is dose-dependent and predictable

Idiosyncratic drug-induced liver injury is unpredictable and generally not related to dose

Susceptibility to idiosyncratic drug-induced liver injury has a genetic component

Drug-induced liver injury is broadly classified into intrinsic and idiosyncratic forms

Oncological agents, specifically immune checkpoint inhibitors and tyrosine kinase inhibitors, represent an increasing cause of idiosyncratic drug-induced liver injury

Corticosteroids serve as the mainstay of medical therapy for immune checkpoint inhibitor-induced liver injury

A higher medication dose is a risk factor for drug-induced liver injury

Idiosyncratic drug-induced liver injury from phenytoin or trimethoprim-sulfamethoxazole can present with DRESS syndrome, featuring fever, rash, and eosinophilia

Prompt discontinuation of the suspected causative agent is a critical intervention in the management of drug-induced liver injury

A short course of corticosteroids can be used to treat autoimmune-like drug-induced liver injury caused by nitrofurantoin or minocycline

Reported cases of cholestatic drug-induced liver injury caused by anabolic steroids have decreased as of November 2026

The latency period between starting a causative medication and the manifestation of drug-induced liver injury is typically three to six months